Trending Stories on Eyewire+
Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfolio
Bausch + Lomb announced that an affiliate has acquired?Elios Vision,?developer of the ELIOS?procedure, a?minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser.?Financial terms of the deal were not disclosed.?
According to B+L, the acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants.??
“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address... Read More
EssilorLuxottica Acquires Espansione Group, Provider of Noninvasive Ophthalmic Medical Devices
Optical giant EssilorLuxottica announced it is acquiring?Italy-based Espansione Group, a provider of noninvasive medical devices?for the diagnosis and treatment of dry eye, ocular surface and retinal diseases. Financial terms of the deal were not disclosed.?
Espansione Group provides devices in more than 40 countries?with photobiomodulation (PBM) technology called the Light Modulation Low-level Light Therapy (LLLT) for use in?ophthalmology and dermatology, along with the Intense Pulsed Light (IPL) technology.
“We are pleased to welcome the pioneering Espansione into our group. This investment, proudly made in one of our home countries, will expand... Read More
Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TED
Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED).
“We are extremely pleased to announce better-than-expected THRIVE-2 results generated in the broadest population of chronic TED patients studied in a global phase 3 study to date. We believe that these efficacy and safety results in only five infusions, combined with our compelling data from THRIVE, confirm the potential of veli to be... Read More
EyewireTV | 12.11.2024
New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Click here to check it out!
Latest In Podcasts
领英推荐
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?
What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitamins. Click here to catch the latest episode.
Meibomian Gland Probing
This month on To the Point, learn about meibomian gland probing in patients with dry eye with Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO. Their guest, Rana Taji, OD, MSc, FAAO, explains what it is, how to do it, why to do it, and more. Catch the latest episode here!
Eyewire News: The Podcast
New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Catch the latest episodes here!
Latest in Subspecialties:
Thank you for reading! We'll be back next week with another edition of?Eyewire+ Weekly Digest. For the most up to date news, please visit us at Eyewire+.